Third Rock Ventures V, L.P.
Director at Rapport Therapeutics.
- Rank
- 530th of 813
- Companies held
- 1
- Largest holding
- RAPP, 100.0% of total
- Latest SEC filing
- Oct 30, 2026
- Listed but not counted
- $73.8M
What the $154M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP Common Stock | Directly | 6,518,620 | $23.59 | $154M | 100.0% | Form 4, Oct 30, 2026 |
Share counts are the amounts Third Rock Ventures V, L.P. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Third Rock Ventures V, L.P.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP Common Stock | Through Third Rock Ventures VI, L.P. Held by a company or fund the insider manages | 2,159,694 | $23.59 | $50.9M | — | Form 4, Oct 30, 2026 |
| Rapport Therapeutics RAPP Common Stock | Through Third Rock Ventures VI, L.P. Held by a company or fund the insider manages | 969,218 | $23.59 | $22.9M | — | Form 4, May 26, 2026 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 527 | ALS Invest 1 B.V. 10% owner, Amylyx Pharmaceuticals | $154M |
| 528 | Boxer Capital Management, LLC Insider, Tango Therapeutics | $154M |
| 529 | Yorktown Energy Partners IX, L.P. 10% owner, Riley Exploration Permian | $154M |
| 530 | Third Rock Ventures V, L.P. Director, Rapport Therapeutics | $154M |
| 531 | New Enterprise Associates 14, L.P. 10% owner, Enliven Therapeutics | $153M |
| 532 | Mpm Asset Management LLC 10% owner, Aktis Oncology | $153M |
| 533 | RC IV Cayman ICW Equity LLC Insider, Driven Brands Holdings | $152M |
Other Rapport Therapeutics insiders
All RAPP insiders- Steven M. Paul$13.1MDirector. #3875 overall
- Abraham Ceesay$13.0MChief Executive Officer. #6744 overall
- David Bredt$9.3MChief Scientific Officer. #9295 overall
- John Maraganore$222KDirector. #1983 overall
Questions
How much stock does Third Rock Ventures V, L.P. own?
Third Rock Ventures V, L.P. holds $153,774,246 in listed stock based on SEC filings and current prices, mostly Rapport Therapeutics (RAPP). That ranks 530th on the Stock Rich List.
Is this Third Rock Ventures V, L.P.'s net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Third Rock Ventures V, L.P. last buy or sell stock?
The most recent open-market trade on file is a sale of 18,572 RAPP shares on May 26, 2026 at $40.05.